Cognetivity Neurosciences Ltd.
CGNSF · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $0 | $0 | $0 |
| Gross Profit | -$2 | -$0 | -$0 | -$0 |
| % Margin | -4,694.9% | – | – | – |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $5 | $12 | $2 | $2 |
| SG&A Expenses | $6 | $12 | $2 | $2 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $0 |
| Other Operating Expenses | -$2 | -$4 | -$1 | $0 |
| Operating Expenses | $4 | $9 | $1 | $3 |
| Operating Income | -$6 | -$13 | -$2 | -$3 |
| % Margin | -13,866.4% | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | $0 | $0 |
| Pre-Tax Income | -$7 | -$13 | -$2 | -$3 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$7 | -$13 | -$2 | -$3 |
| % Margin | -16,386.3% | – | – | – |
| EPS | -0.087 | -0.18 | -0.033 | -0.058 |
| % Growth | 51.4% | -447.1% | 43.3% | – |
| EPS Diluted | -0.087 | -0.18 | -0.033 | -0.058 |
| Weighted Avg Shares Out | 85 | 73 | 59 | 46 |
| Weighted Avg Shares Out Dil | 85 | 73 | 59 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$13 | -$2 | -$3 |
| % Margin | -14,067.1% | – | – | – |